A new product pricing model using intracorporate market perceptions to extract the value of additional information

PharmacoEconomics

Volumn 14, Issue 1, 1998, Pages 71-77

  Woodward, Robert S ^a,c   Amir, Leah ^b   Schnitzler, Mark A ^a   Brennan, Daniel C ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Inst for Qual Resource Management   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CALCULATION; COMPUTER PROGRAM; ECONOMIC ASPECT; MARKETING; PRIORITY JOURNAL;

DRUG COSTS; DRUG INDUSTRY; ECONOMICS, PHARMACEUTICAL; HUMANS; MODELS, ECONOMIC; UNITED STATES;

EID: 0031875239     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199814010-00007     Document Type: Article

References (12)

1. Berndt E, Wilinsky M, Fazio A, et al. Fluconazole DUE: results empower staff pharmacists. ASHP Midyear Clinical Meeting; 1994 Dec 29; Miami Beach, P-169 (D)
2. Lipsy RJ. Institutional formularies: the relevance of pharmacoeconomic analysis to formulary decisions. Pharmacoeconomics 1992; 1 (4): 265-81
3. Pharmaceutical Manufacturers Association. R&D; the key to innovation [online]. Available from: URL: http://www.-phrma.org/facts/industry/profile97/chap2.html [Accessed 1998 Apr 22]
4. Coy P, Gross N, Sansoni S, et al. R&D scoreboard. Business Week 1994 Jun 27: 81-91
5. Bobula JD. New era in pharmaceutical pricing. J Res Pharm Econ 1996; 7 (1-2): 89-99
6. Lu J, Comanor WS. Strategic pricing of new pharmaceuticals. Rev Econ Stat 1998; 80 (1): 108-18
7. Kolassa M. Pharmaceutical pricing at the change of the millennia. J Pharm Mark Manage 1996; 10 (2-3): 109-20
8. Clemens K, Garrison Jr LP, Jones A, et al. Strategic use of pharmacoeconomic research in early drug development and global pricing. Pharmacoeconomics 1992; 4 (5): 315-22
9. DeBenedette V. Now what [abstract]? Drug Top 1996; 140: 94
10. McCarthy B. Moving, proving market share. Manage Healthcare 1996; 6 Suppl. 8: S17-20
11. Monaghan MJ, Monaghan MS. Do market components account for higher U. S. prescription prices? Ann Pharmacother 1996; 30: 1489-94
12. Woodward RS, Boxerman SB, Schnitzler MA, et al. Optimum investments in project evaluations: the cost-effectiveness of cost-effectiveness analyses. J Med Syst 1996; 20: 385-93